Subscribe
Core coverageKOD

Company profile / KOD

Kodiak Sciences

Clinaptis stanceNeutral
ConvictionHigh
Ticker
KOD
Exchange
NASDAQ
Coverage
Standard profile
Updated
Oct 3, 2026
Ophthalmology / Retinal Disease

Precommercial retina-focused biotechnology company developing long-acting and multi-mechanistic intravitreal therapies. The late-stage portfolio is led by Zenkuda (tarcocimab tedromer), an anti-VEGF Antibody Biopolymer Conjugate with Phase 3 data across diabetic retinopathy, retinal vein occlusion and wet AMD; KSI-501, a bispecific IL-6/VEGF therapy in Phase 3 wet AMD and DME development; and KSI-101, an unconjugated bispecific IL-6/VEGF protein in Phase 3 development for macular edema secondary to inflammation.

01 / Clinaptis view

The current read

DAYBREAK exceeded our base case. Zenkuda preserved vision while 54% of patients reached q24w and 62% reached q20–24w, validating the durability thesis we had treated as the harder part of the readout.

  1. The initial move into the low-$60s tracked our ~$63 Clean re-rate case; at ~$85–90, the stock has moved toward our ~$89 Differentiated-franchise value. The data earned the re-rate.
  2. At current levels, however, much of the commercial validation is already priced in.
02 / Consensus gap

Where the market may differ

DAYBREAK settled clinical differentiation; it did not settle commercial durability. At ~$85–90, the market is valuing Zenkuda close to our pre-readout franchise case, which assumed its q20–24w advantage would translate into durable share.

  1. That remains the open question: Eylea HD is extending the competitive bar, and longer injection intervals do not necessarily mean equally fewer clinic visits. We would distinguish a strong DAYBREAK result from a fully validated retinal franchise.
Coverage state
Standard profile
Work status
Complete
What the review turns on
Key variable

Whether Zenkuda's q20–24w dosing advantage translates into durable retinal share and fewer real-world clinic visits as Eylea HD extends the competitive bar

Next catalyst

KSI-101 PEAK Pivotal Analysis 1 topline · December 2026

03 / Pipeline

Key programs

3 assets · 5 programs

AssetIndicationStageNext event
Zenkuda (tarcocimab tedromer)
Wet age-related macular degeneration
Phase 3 / BLA-facing
DAYBREAK completed: vision preserved; 54% of patients reached q24w and 62% reached q20–24w
Diabetic retinopathy / Retinal vein occlusion
Phase 3 complete / BLA preparation
Continued preparation of a multi-indication Zenkuda BLA following positive GLOW1, GLOW2 and BEACON Phase 3 studies
KSI-501
Wet age-related macular degeneration
Phase 3
DAYBREAK controlled efficacy and safety follow-up; fixed q8w dosing with additional individualized monthly dosing as needed
Diabetic macular edema
Phase 3
ALTO global Phase 3 superiority study versus aflibercept actively enrolling
KSI-101
Macular edema secondary to inflammation
Phase 3
PEAK Pivotal Analysis 1 topline data expected December 2026; second PEAK/PINNACLE pivotal analysis expected Q2 2027
04 / Connected research

Published on KOD

View full archive
  1. 01

    Kodiak's DAYBREAK: Likely to Work, Less Likely to Matter

    Non-inferiority remains the base case (~63%) — but the pass is more likely to be commercially thin than differentiated, and that is what the stock trades on.

    Read